On July 31, the FDA announced it would move forward with regulations to restrict cutting edge laboratory developed tests (LDTs), which have not required FDA approval before because they are not marketed to consumers. The new regulations would change that. Why should you care? – Read about it here.
Whose interests is the FDA protecting? Not Lyme patients, apparently